Trials / Recruiting
RecruitingNCT06414954
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 3 Dose Levels of NMD670 Over 21 Days in Adult Patients With AChR/MuSK-Ab+ Myasthenia Gravis
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 84 (estimated)
- Sponsor
- NMD Pharma A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NMD670 | Tablets taken twice a day for 21 days |
| DRUG | Placebo | Tablets taken twice a day for 21 days |
Timeline
- Start date
- 2024-05-16
- Primary completion
- 2026-05-01
- Completion
- 2026-05-01
- First posted
- 2024-05-16
- Last updated
- 2026-04-13
Locations
40 sites across 10 countries: United States, Belgium, Denmark, France, Georgia, Italy, Netherlands, Poland, Serbia, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06414954. Inclusion in this directory is not an endorsement.